Company news

SciSparc Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility

July 6, 2022

SciSparc Board of Directors to Promote Buyback Program of up to $1 Million

July 5, 2022

SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome

June 28, 2022

SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

June 22, 2022

SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

June 14, 2022

SciSparc's Board of Directors Provides Strategic Decision

June 8, 2022

SciSparc Ltd. Announces Closing of $10 Million Private Placement Priced At-the-Market

May 31, 2022

SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market

May 26, 2022

SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome

May 25, 2022

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors

May 9, 2022

SciSparc Files Annual Report for Year Ended December 31, 2021 and Provides Corporate Update

May 1, 2022

SciSparc Announces Closing of New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases

March 30, 2022

Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

March 29, 2022

SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial

March 16, 2022

SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases

March 9, 2022

SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals

March 7, 2022

SciSparc Presents New Leadership Lineup

January 26, 2022

SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110

January 17, 2022

SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease

January 5, 2022

SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders

January 3, 2022

SciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today

December 21, 2021

← Newer news releases

Decks

The 5 newest of 10 decks. Every deck is listed under its year.